安徽医科大学学报
安徽醫科大學學報
안휘의과대학학보
ACTA UNIVERSITY MEDICINALIS ANHUI
2015年
5期
628-631
,共4页
于婷%赵洪萍%周颖%赵卫东%刘培淑
于婷%趙洪萍%週穎%趙衛東%劉培淑
우정%조홍평%주영%조위동%류배숙
卵巢肿瘤%自噬%LC3-Ⅱ
卵巢腫瘤%自噬%LC3-Ⅱ
란소종류%자서%LC3-Ⅱ
ovarian neoplasm%autophagy%LC3-Ⅱ
目的:本研究检测微管轻链Ⅰ蛋白3-Ⅱ型(LC3-Ⅱ)在不同卵巢肿瘤组织中的表达情况,探讨其与浆液性卵巢癌及粘液性卵巢癌发生、发展的相关性和意义。方法选取204例上皮性卵巢肿瘤标本,其中,卵巢浆液性囊腺瘤46例,交界性浆液性肿瘤28例,浆液性囊腺癌40例,黏液性囊腺瘤32例,交界性黏液性囊腺瘤30例,黏液性囊腺癌28例,另选取正常卵巢上皮组织28例作为对照。使用 SP 法检测正常卵巢上皮组织、上皮性卵巢肿瘤组织中 LC3-Ⅱ的表达,并结合浆液性癌、黏液性癌临床病理因素进行分析。结果①正常卵巢上皮中 LC3-Ⅱ无表达,卵巢良性浆液性囊腺瘤、交界性浆液性肿瘤及浆液性癌中 LC3-Ⅱ的阳性率分别为4.5%、71.0%、95.0%,交界性浆液性肿瘤和浆液性癌中 LC3-Ⅱ的表达明显高于良性浆液性囊腺瘤,差异有统计学意义(P <0.01)。卵巢良性黏液性囊腺瘤、交界性黏液性肿瘤及黏液性癌中 LC3-Ⅱ的阳性率分别为6.7%、66.7%、92.9%,交界性浆液性肿瘤和浆液性癌中 LC3-Ⅱ的表达明显高于良性浆液性囊腺瘤,差异有统计学意义(P <0.01);②在40例卵巢浆液性癌、28例卵巢黏液性癌中,LC3-Ⅱ表达与患者年龄、FIGO 分期及病理学分级等临床病理特征均无关。结论 LC3-Ⅱ在卵巢上皮性交界性肿瘤、癌中表达增高,自噬活性增强,可能与卵巢上皮性恶性肿瘤的进展有关。
目的:本研究檢測微管輕鏈Ⅰ蛋白3-Ⅱ型(LC3-Ⅱ)在不同卵巢腫瘤組織中的錶達情況,探討其與漿液性卵巢癌及粘液性卵巢癌髮生、髮展的相關性和意義。方法選取204例上皮性卵巢腫瘤標本,其中,卵巢漿液性囊腺瘤46例,交界性漿液性腫瘤28例,漿液性囊腺癌40例,黏液性囊腺瘤32例,交界性黏液性囊腺瘤30例,黏液性囊腺癌28例,另選取正常卵巢上皮組織28例作為對照。使用 SP 法檢測正常卵巢上皮組織、上皮性卵巢腫瘤組織中 LC3-Ⅱ的錶達,併結閤漿液性癌、黏液性癌臨床病理因素進行分析。結果①正常卵巢上皮中 LC3-Ⅱ無錶達,卵巢良性漿液性囊腺瘤、交界性漿液性腫瘤及漿液性癌中 LC3-Ⅱ的暘性率分彆為4.5%、71.0%、95.0%,交界性漿液性腫瘤和漿液性癌中 LC3-Ⅱ的錶達明顯高于良性漿液性囊腺瘤,差異有統計學意義(P <0.01)。卵巢良性黏液性囊腺瘤、交界性黏液性腫瘤及黏液性癌中 LC3-Ⅱ的暘性率分彆為6.7%、66.7%、92.9%,交界性漿液性腫瘤和漿液性癌中 LC3-Ⅱ的錶達明顯高于良性漿液性囊腺瘤,差異有統計學意義(P <0.01);②在40例卵巢漿液性癌、28例卵巢黏液性癌中,LC3-Ⅱ錶達與患者年齡、FIGO 分期及病理學分級等臨床病理特徵均無關。結論 LC3-Ⅱ在卵巢上皮性交界性腫瘤、癌中錶達增高,自噬活性增彊,可能與卵巢上皮性噁性腫瘤的進展有關。
목적:본연구검측미관경련Ⅰ단백3-Ⅱ형(LC3-Ⅱ)재불동란소종류조직중적표체정황,탐토기여장액성란소암급점액성란소암발생、발전적상관성화의의。방법선취204례상피성란소종류표본,기중,란소장액성낭선류46례,교계성장액성종류28례,장액성낭선암40례,점액성낭선류32례,교계성점액성낭선류30례,점액성낭선암28례,령선취정상란소상피조직28례작위대조。사용 SP 법검측정상란소상피조직、상피성란소종류조직중 LC3-Ⅱ적표체,병결합장액성암、점액성암림상병리인소진행분석。결과①정상란소상피중 LC3-Ⅱ무표체,란소량성장액성낭선류、교계성장액성종류급장액성암중 LC3-Ⅱ적양성솔분별위4.5%、71.0%、95.0%,교계성장액성종류화장액성암중 LC3-Ⅱ적표체명현고우량성장액성낭선류,차이유통계학의의(P <0.01)。란소량성점액성낭선류、교계성점액성종류급점액성암중 LC3-Ⅱ적양성솔분별위6.7%、66.7%、92.9%,교계성장액성종류화장액성암중 LC3-Ⅱ적표체명현고우량성장액성낭선류,차이유통계학의의(P <0.01);②재40례란소장액성암、28례란소점액성암중,LC3-Ⅱ표체여환자년령、FIGO 분기급병이학분급등림상병리특정균무관。결론 LC3-Ⅱ재란소상피성교계성종류、암중표체증고,자서활성증강,가능여란소상피성악성종류적진전유관。
Objective To investigate the expression of microtubule-associated protein light chain 3-Ⅱ(LC3-Ⅱ) in the epithelial ovarian carcinoma and explore their correlations to the tumorigenesis and development of epithelial o-varian carcinoma. Methods 204 specimens with different-type epithelial ovarian tumors,including 46 with serous cystadenoma,28 with borderline serous cystadenoma,40 with serous cystadenocarcinoma,32 with mucinous cystade-noma,32 with borderline mucinous cystadenoma,28 with mucinous cystadenocarcnoma,were selected in our study. Immunohistochemistry was employed to detect the expression of LC3-Ⅱ. The correlations between expression of LC3-Ⅱ and both the pathological features and clinical manifestations of 68 epithelial ovarian cancer patients were analyzed. Results The positive rates of LC3-Ⅱ were significantly higher in epithelial ovarian cancinoma and bor-derline ovarian tumors than benign epithelial ovarian tumors. (In ovarian serous tumor,95% and 71% vs 4. 5% ,P< 0. 01;in ovarian mucinous tumor, 92. 9% and 66. 7% vs 6. 7% ,P < 0. 01) ② In the serous cystadenocarcinoma and mucinous cystadenocarcnoma,the expression of LC3-Ⅱ was not correlated to age, FIGO stage and histological grade. Conclusion Expression of LC3-Ⅱ is up-regulated in epithelial ovarian cancer tissues. The increase of au-tophagic capacity may relate to the development of epithelial ovarian cancer.